Drug
Z-endoxifen
Z-endoxifen is a pharmaceutical drug with 5 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
4(80%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
4
80%
Ph phase_1
1
20%
Phase Distribution
1
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
5
all time
Status Distribution
Active(4)
Completed(1)
Detailed Status
Recruiting3
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
4
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (20.0%)
Phase 24 (80.0%)
Trials by Status
recruiting360%
active_not_recruiting120%
completed120%
Recent Activity
4 active trials
Showing 5 of 5
recruitingphase_2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT01042379
recruitingphase_2
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT06075953
completedphase_1
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
NCT01273168
recruitingphase_2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05607004
active_not_recruitingphase_2
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
NCT05068388
Clinical Trials (5)
Showing 5 of 5 trials
NCT01042379Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT06075953Phase 2
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT01273168Phase 1
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
NCT05607004Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05068388Phase 2
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5